ExoVasc® PEARS

1,400 patient milestone reached

Exstent Ltd, developer and manufacturer of the ExoVasc® Personalised External Aortic Root Support (PEARS), is pleased to announce that more than 1,400 patients have now received an ExoVasc®.

The device offers an alternative to valve sparing root replacement (VSRR) and total root replacement (TRR) by supporting the aortic wall, preventing further dilatation and negating the requirement for lifelong anti-coagulants. It can also be used to support the pulmonary autograft when the native aortic valve is replaced as part of the Ross procedure.

Dr Ana Redondo awarded the EACTS Presidents Choice Award at EACTS 2025

Tal Golesworthy meets patient 1,338: Richard Krajicek

Interested in our patient experiences?

We develop medical devices that manage aortic dilation and minimise the risk of aortic dissection.

quick links

statements & policies

Our contact details

The staff of Exstent Limited are not medically qualified and are thus not able to provide clinical advice or answer questions of a clinical nature. We may direct your attention to publications in peer-reviewed journals that provide clinical information or provide information based upon personal experience. However, for any questions of a clinical nature patients are recommended to consult a qualified clinician.